Nicergolina Slavia (Nicergoline)

Nicergoline acts on the cerebrovascular system and is indicated for several vascular‑related conditions.

• Cerebrovascular disorders: enhances cerebral blood flow, helping to alleviate symptoms associated with reduced perfusion such as dizziness, headache, and transient ischemic attacks.
• Vascular dementia: may improve cognitive function by increasing neuronal metabolism in affected brain regions, potentially supporting memory, attention, and executive tasks.
• Peripheral vascular disease: promotes peripheral circulation, potentially reducing claudication, ischemic discomfort, and improving walking distance in patients with arterial insufficiency.

• Nicergoline exerts its effect by selectively antagonizing alpha‑adrenergic receptors while simultaneously agonizing serotonin (5‑HT1) receptors in the vascular smooth muscle. This dual action leads to vasodilation of cerebral and peripheral vessels, increased blood flow, and enhanced oxygen and glucose delivery to neuronal tissue, thereby supporting metabolic activity. The drug also modulates platelet aggregation and reduces blood viscosity, contributing further to improved microcirculatory dynamics.

Nicergoline may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset often occurring after the first dose.
• Dizziness: transient light‑headedness that may resolve with continued therapy.
• Headache: mild to moderate pain, usually temporary.
• Gastrointestinal upset: includes abdominal discomfort, dyspepsia, or loose stools.
• Hypotension: slight reduction in blood pressure, generally asymptomatic.
• Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure that may cause fainting.
• Cardiac arrhythmia: irregular heart rhythm requiring medical evaluation.
• Hepatic dysfunction: elevated liver enzymes or jaundice indicating liver stress.
• Allergic reactions: rash, pruritus, or angioedema that may need discontinuation.
• Priapism: prolonged painful erection requiring urgent care.

When prescribing Nicergoline, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: monitor renal function and adjust therapy if necessary.
• Hepatic disease: use cautiously and observe liver function tests regularly.
• Concomitant antihypertensives: assess blood pressure to avoid additive hypotensive effects.
• History of ergotism or peripheral vascular disease: avoid use due to risk of vasospasm.
• Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
• Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Nicergoline can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): combined use may cause severe hypertension or serotonin syndrome.
• Other ergot derivatives: additive vasoconstrictive effects increase risk of ischemia.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nicergoline plasma levels.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: enhanced blood‑pressure lowering effect, monitor BP.
• Selective serotonin reuptake inhibitors (SSRIs): potential for increased serotonergic activity.
• Anticoagulants (e.g., warfarin): possible alteration of bleeding risk, require INR monitoring.